Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00452725 | Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome | PHASE3 | COMPLETED | 36 | — | — | Oct 1, 1997 | Jul 1, 2010 | Oct 5, 2010 | 1 | France |
| Name | Type | Description |
|---|---|---|
| MAXOMAT ®, biosynthetic growth hormone | DRUG | 2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration |
Inclusion Criteria: * Children and adolescents with Noonan's syndrome with a height \< -2 SD and no progressive cardiopathy Exclusion Criteria: * Age \< 3 years * Height ≥ -2 SD The above information is not intended to contain all considerations relevant to a patient's potential participation in...